Search

Your search keyword '"Bourdin, Arnaud"' showing total 93 results

Search Constraints

Start Over You searched for: Author "Bourdin, Arnaud" Remove constraint Author: "Bourdin, Arnaud" Publisher elsevier bv Remove constraint Publisher: elsevier bv
93 results on '"Bourdin, Arnaud"'

Search Results

1. Anti-IL-4R versus Anti-IL-5/5R after Anti-IL-5/5R failure in asthma: an emulated target trial

4. Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients with Uncontrolled Moderate-To-Severe Asthma: the VESTIGE Trial

5. Longitudinal patterns of intermittent oral corticosteroid use for asthma in the UK

6. Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”

7. Long-Term Efficacy Of Dupilumab In Patients With Moderate-To-Severe Type 2 Asthma Stratified By Baseline Characteristics During The 96-Week TRAVERSE Study

8. Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study

9. CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma

10. Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-asthma Biologics

11. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

13. Global access and patient safety in the transition to environmentally friendly respiratory inhalers: the Global Initiative for Asthma perspective

14. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry

15. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2021 update. Full-length version

16. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: the NAVIGATOR study

18. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy

19. Germline Mutations of Telomere-Related Genes are a Major Risk Factor for Liver Disease: A Multicentric Transversal Study

20. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

21. CLINICAL OUTCOMES IN PATIENTS WITH SEVERE ASTHMA WHO HAD OR HAD NOT INITIATED BIOLOGIC THERAPY: RESULTS FROM THE CLEAR STUDY

22. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline

23. CLINICAL OUTCOMES AND EMERGENCY HEALTH CARE UTILIZATION IN PATIENTS WITH SEVERE ASTHMA WHO CONTINUED, SWITCHED, OR STOPPED BIOLOGIC THERAPY: RESULTS FROM THE CLEAR STUDY

27. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases

28. Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial

29. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

31. Position paper of the French Society of Respiratory Diseases regarding pharmacological treatment optimization for stable COPD in 2021

32. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion

34. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

35. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial

36. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease

38. Defining a Severe Asthma Super-Responder: Findings from a Delphi Process

43. Eosinophilic and Noneosinophilic Asthma

45. Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC

47. Potential Severe Asthma Hidden in UK Primary Care

49. Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C

50. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Catalog

Books, media, physical & digital resources